Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells

Hepatology Research

Volumn 39, Issue 6, 2009, Pages 601-608

  Bechmann, Lars P ^a,b   Zahn, Denis ^a   Gieseler, Robert K ^a   Fingas, Christian D ^a   Marquitan, Guido ^a   Jochum, Christoph ^a   Gerken, Guido ^a   Friedman, Scott L ^b   Canbay, Ali ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Free fatty acids; Profibrogenic activation; Resveratrol

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; FAS ANTIGEN; FATTY ACID; OLEIC ACID; PALMITIC ACID; PROTEIN BCL 2; PROTEIN MCL 1; RESVERATROL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR 1;

ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; INCUBATION TIME; LD 50; LIVER CELL; LIVER FIBROSIS; OBESITY; PRIORITY JOURNAL; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; STELLATE CELL; UPREGULATION;

EID: 66449085300     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00485.x     Document Type: Article

References (36)

1. St leger AS, Cochrane AL, Moore F. Factors associated with cardiac mortality in developed countries with particular reference to the consumption of wine. Lancet 1979; 1 (8124): 1017-20.
2. Sun AY, Simonyi A, Sun GY. The "French Paradox" and beyond: neuroprotective effects of polyphenols. Free Radic Biol Med 2002; 32: 314-18.
3. Shimada K, Watanabe H, Hosoda K, Takeuchi K, Yoshikawa J. Effect of red wine on coronary flow-velocity reserve. Lancet 1999; 354: 1002.
4. van Velden DP, Mansvelt EP, Fourie E, Rossouw M, Marais AD. The cardioprotective effect of wine on human blood chemistry. Ann N Y Acad Sci 2002; 957: 337-40.
5. Frankel EN, Kanner J, German JB et al. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993; 341: 454-7.
6. Opie LH, Lecour S. The red wine hypothesis: From concepts to protective signalling molecules. Eur Heart J 2007; 28: 1683-93.
7. de Gaetano G, De Curtis A, di Castelnuovo A et al. Antithrombotic effect of polyphenols in experimental models: A mechanism of reduced vascular risk by moderate wine consumption. Ann N Y Acad Sci 2002; 957: 174-88.
8. Sarr M, Chataigneau M, Martins S et al. Red wine polyphenols prevent angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase. Cardiovasc Res 2006; 71: 794-802.
9. Sato M, Maulik N, Das DK. Cardioprotection with alcohol: Role of both alcohol and polyphenolic antioxidants. Ann N Y Acad Sci 2002; 957: 122-35.
10. Athar M, Back JH, Tang X et al. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007; 224: 274-83.
11. Das S, Das DK. Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets 2007; 6: 168-73.
12. Olson ER, Naugle JE, Zhang X et al. Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol 2005; 288: H1131-8.
13. Bujanda L, Garcia-Barcina M, Gutierrez-de Juan V et al. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol 2006; 6: 35.
14. Baur JA, Pearson KJ, Price NL et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-42.
15. Muriel P, Rivera-Espinoza Y. Beneficial drugs for liver diseases. J Appl Toxicol 2008; 28: 93-103.
16. Kawada N, Seki S, Inoue M, Kuroki T. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998; 27: 1265-74.
17. Souza IC, Martins LA, Coelho BP et al. Resveratrol inhibits cell growth by inducing cell cycle arrest in activated hepatic stellate cells. Mol Cell Biochem 2008; 315: 1-7.
18. Pusl T, Wild N, Vennegeerts T et al. Free fatty acids sensitize hepatocytes to bile acid-induced apoptosis. Biochem Biophys Res Commun 2008; 371: 441-5.
19. Canbay A, Gieseler RK, Gores GJ, Gerken G. The relationship between apoptosis and non-alcoholic fatty liver disease: An evolutionary cornerstone turned pathogenic. Z Gastroenterol 2005; 43: 211-17.
20. Lu LG, Zeng MD, Li JQ et al. Study on the role of free fatty acids in proliferation of rat hepatic stellate cells (II). World J Gastroenterol 1998; 4: 500-2.
21. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-35.
22. Ramadori G. The stellate cell (Ito-cell, fat-storing cell, lipocyte, perisinusoidal cell) of the liver. New insights into pathophysiology of an intriguing cell. Virchows Arch B Cell Pathol Incl Mol Pathol 1991; 61: 147-58.
23. Friedman SL. Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-72.
24. Xu L, Hui AY, Albanis E et al. Human hepatic stellate cell lines, LX-1 and LX-2: New tools for analysis of hepatic fibrosis. Gut 2005; 54: 142-51.
25. Sagawa N, Fujita H, Banno Y et al. Gelsolin suppresses tumorigenicity through inhibiting PKC activation in a human lung cancer cell line, PC10. Br J Cancer 2003; 88: 606-12.
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
27. Greystoke A, Cummings J, Ward T et al. Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 2008; 19: 990-5.
28. Wedemeyer I, Bechmann L, Odenthal M et al. Adiponectin inhibits steatotic CD95/Fas upregulation by hepatocytes: Therapeutic implications for hepatitis C. J Hepatol 2009; 50: 140-9.
29. Lancon A, Hanet N, Jannin B et al. Resveratrol in human hepatoma HepG2 cells: Metabolism and inducibility of detoxifying enzymes. Drug Metab Dispos 2007; 35: 699-703.
30. Zhou X, Jamil A, Nash A et al. Impaired proteolysis of collagen I inhibits proliferation of hepatic stellate cells: Implications for regulation of liver fibrosis. J Biol Chem 2006; 281: 39757-65.
31. Puri P, Baillie RA, Wiest MM et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-90.
32. Canbay A, Feldstein AE, Higuchi H et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38: 1188-98.
33. Feldstein AE, Werneburg NW, Canbay A et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004; 40: 185-94.
34. Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000; 6: 920-3.
35. Li JT, Liao ZX, Ping J, Xu D, Wang H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol 2008; 43: 419-28.
36. Yu C, Shin YG, Chow A et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res 2002; 19: 1907-14.